Henshaw Capital’s PTC Therapeutics PTCT Stock Holding History

Henshaw Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,460	Closed	-$257K	–	288
2023 Q3	$257K	Buy	11,460 +4,261	+59%	+$158K	0.01%	247
2023 Q2	$293K	Buy	7,199 +958	+15%	+$46.9K	0.02%	189
2023 Q1	$302K	Buy	6,241 +703	+13%	+$32.1K	0.02%	177
2022 Q4	$211K	Hold	5,538	–	–	0.01%	227
2022 Q3	$278K	Hold	5,538	–	–	0.02%	213
2022 Q2	$222K	Hold	5,538	–	–	0.02%	277
2022 Q1	$207K	Hold	5,538	–	–	0.01%	307
2021 Q4	$221K	Hold	5,538	–	–	0.01%	311
2021 Q3	$206K	Hold	5,538	–	–	0.01%	317
2021 Q2	$234K	Hold	5,538	–	–	0.01%	322
2021 Q1	$262K	Buy	5,538 +783	+16%	+$46.5K	0.02%	302
2020 Q4	$290K	Buy	+4,755	New	+$280K	0.02%	262

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Henshaw Capital's PTCT Position: Q4 2023 in Review

Henshaw Capital sold out of PTC Therapeutics (PTCT) in Q4 2023, closing a stake of 11,460 shares — an estimated $257K sold.

Henshaw Capital first reported a position in PTCT in Q4 2020 and held it in 12 quarters. The position peaked at $302K in Q1 2023. 173 funds tracked by Wall St. Rank hold PTCT as of Q4 2023.

Henshaw Capital reported no remaining PTC Therapeutics position as of Q4 2023 after selling out during the quarter.
Henshaw Capital sold 11,460 PTC Therapeutics shares in Q4 2023, an estimated $257K.
Henshaw Capital first reported a position in PTC Therapeutics in Q4 2020 and held it in 12 quarters.
Henshaw Capital's PTC Therapeutics position peaked at $302K in Q1 2023.
173 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2023.

Based on Henshaw Capital's 13F filing for Q4 2023, filed 28 May 2026.